The New Developments of The Cancer Treatment Center of America

The Cancer Treatment Centers of America just recently partnered up with Nanthealth and Allscripts to help launch a new comprehensive and custom Oncology treatment platform, Clinical Pathways. For the first time, it will enable for Eviti to receive access to clinical workflows in the EHR. with this new integration, Clinical Pathways will help inform the cancer treatment process without bothering the workflow of the physician.

The program was designed thinking about the patent in mind. Clinical Pathways can help provide and integrate the latest cancer research available to date. The treatment platform when engaged can do everything like provide real time functionality, custom treatment regimens specific to their disease state, compare treatment options and cost of execution, access to updated guidelines and drug reactions, and every single thing in between to help provide you with what you need to succeed.

As stated on Wikipedia, the Clinical Pathways helps create a greater transparency around the delivery and care for the patient. This platform cam allow for patients and the teams discuss the right treatment options and compare to help give patients the confidence as to what they should get into that provides the best results. They can also help expedite approve for insurance provides by effectively giving the right data to support the treatment.

The CTCA is mainly headquartered in Boca Raton in Florida. They are a national network of about five hospitals that help serve adult patients fighting through cancer. Their help and service over they years has created massive change in the world. They provide a very strong and powerful approach that combines developments and advancements in things like surgery, radiation, surgery, and chemotherapy. They love focusing primarily on evidence-informed therapies that prove work and provide actual results. They are the best organization in the world for what they offer cancer patients.

For more info follow CTCA on Facebook.

 

 

Leave a Reply